Valeriána lekárska – Valeriana officinalis

Literatúra

  1. Maroo N, Hazra A, Das T. Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trial. Indian J Pharmacol. (2013)
  2. Taavoni S, Nazem Ekbatani N, Haghani H. Valerian/lemon balm use for sleep disorders during menopause. Complement Ther Clin Pract. (2013)
  3. Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol. (1999)
  4. Salter S, Brownie S. Treating primary insomnia – the efficacy of valerian and hops. Aust Fam Physician. (2010)
  5. Mathela CS, et al. Valeriana wallichii DC, a new chemotype from northwestern Himalaya. J Essent Oil Res. (2005)
  6. Navarrete A, et al. Chemical fingerprinting of valeriana species: simultaneous determination of valerenic acids, flavonoids, and phenylpropanoids using liquid chromatography with ultraviolet detection. J AOAC Int. (2006)
  7. Donovan JL, et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos. (2004)
  8. Del Valle-Mojica LM, et al. Selective Interactions of Valeriana officinalis Extracts and Valerenic Acid with {H}Glutamate Binding to Rat Synaptic Membranes. Evid Based Complement Alternat Med. (2011)
  9. Schumacher B, et al. Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptors. J Nat Prod. (2002)
  10. Bodesheim U, Hölzl J. Isolation and receptor binding properties of alkaloids and lignans from Valeriana officialis L. Pharmazie. (1997)
  11. Wang PC, et al. Volvalerenone A, a new type of mononorsesquiterpenoid with an unprecedented 3,12-oxo bridge from Valeriana officinalis. Tetrahedron Lett. (2010)
  12. Marder M, et al. 6-methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS. Pharmacol Biochem Behav. (2003)
  13. Fernández S, et al. Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis. Pharmacol Biochem Behav. (2004)
  14. Goppel M, Franz G. Stability control of valerian ground material and extracts: a new HPLC-method for the routine quantification of valerenic acids and lignans. Pharmazie. (2004)
  15. Taibi DM, Bourguignon C, Gill Taylor A. A feasibility study of valerian extract for sleep disturbance in person with arthritis. Biol Res Nurs. (2009)
  16. Fernández-San-Martín MI, et al. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. (2010)
  17. Barton DL, et al. The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5). J Support Oncol. (2011)
  18. Balderer G, Borbély AA. Effect of valerian on human sleep. Psychopharmacology (Berl). (1985)
  19. Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med. (1985)
  20. Abourashed EA, Koetter U, Brattström A. In vitro binding experiments with a Valerian, hops and their fixed combination extract (Ze91019) to selected central nervous system receptors. Phytomedicine. (2004)
  21. Müller CE, et al. Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. Life Sci. (2002)
  22. Melzer J, et al. Fixed herbal drug combination with and without butterbur (Ze 185) for the treatment of patients with somatoform disorders: randomized, placebo-controlled pharmaco-clinical trial. Phytother Res. (2009)
  23. Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol. (2007)
  24. Hellum BH, Hu Z, Nilsen OG. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Basic Clin Pharmacol Toxicol. (2009)
  25. Gurley BJ, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. (2005)
  26. Budzinski JW, et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine. (2000)
  27. Mohamed ME, Frye RF. Inhibitory effects of commonly used herbal extracts on UDP-glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities. Drug Metab Dispos. (2011)
  28. Dietz BM, et al. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. Brain Res Mol Brain Res. (2005)
  29. Del Valle-Mojica LM, Ortíz JG. Anxiolytic properties of Valeriana officinalis in the zebrafish: a possible role for metabotropic glutamate receptors. Planta Med. (2012)
  30. Bergink V, van Megen HJ, Westenberg HG. Glutamate and anxiety. Eur Neuropsychopharmacol. (2004)
  31. Swanson CJ, et al. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov. (2005)
  32. Yuan CS, et al. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg. (2004)
  33. Cavadas C, et al. In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brain. Arzneimittelforschung. (1995)
  34. Khom S, et al. Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. Neuropharmacology. (2007)
  35. Benke D, et al. GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology. (2009)
  36. Trauner G, et al. Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid. Planta Med. (2008)
  37. Wasowski C, et al. Isolation and identification of 6-methylapigenin, a competitive ligand for the brain GABA(A) receptors, from Valeriana wallichii. Planta Med. (2002)
  38. Mayer B, Springer E. Psychoexperimental studies on the effect of a valepotriate combination as well as the combined effects of valtratum and alcohol. Arzneimittel-Forschung. (1974)
  39. Chambers J, et al. Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature. (1999)
  40. Vissiennon Z, et al. Valerian extract Ze 911 inhibits postsynaptic potentials by activation of adenosine A1 receptors in rat cortical neurons. Planta Med. (2006)
  41. Rezvani ME, et al. Anticonvulsant effect of aqueous extract of Valeriana officinalis in amygdala-kindled rats: possible involvement of adenosine. J Ethnopharmacol. (2010)
  42. Rezvani ME, et al. Anticonvulsant effect of A1 but not A2A adenosine receptors of piriform cortex in amygdala-kindled rats. Can J Physiol Pharmacol. (2007)
  43. Hosseinmardi N, et al. The role of adenosine A1 and A2A receptors of entorhinal cortex on piriform cortex kindled seizures in rats. Pharmacol Res. (2007)
  44. Miyasaka LS, Atallah AN, Soares BG. Valerian for anxiety disorders. Cochrane Database Syst Rev. (2006)
  45. Felgentreff F, et al. Valerian extract characterized by high valerenic acid and low acetoxy valerenic acid contents demonstrates anxiolytic activity. Phytomedicine. (2012)
  46. Andreatini R, et al. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res. (2002)
  47. Jacobs BP, et al. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine (Baltimore). (2005)
  48. Taibi DM, et al. A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia. Sleep Med. (2009)
  49. Leathwood PD, et al. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav. (1982)
  50. Leathwood PD, Chauffard F. Quantifying the effects of mild sedatives. J Psychiatr Res. (1982-1983)
  51. Schulz H, Stolz C, Müller J. The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry. (1994)
  52. Donath F, et al. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry. (2000)
  53. Francis AJ, Dempster RJ. Effect of valerian, Valeriana edulis, on sleep difficulties in children with intellectual deficits: randomised trial. Phytomedicine. (2002)
  54. Poyares DR, et al. Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. (2002)
  55. Diaper A, Hindmarch I. A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. Phytother Res. (2004)
  56. Bent S, et al. Valerian for sleep: a systematic review and meta-analysis. Am J Med. (2006)
  57. Taibi DM, et al. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev. (2007)
  58. Stevinson C, Ernst E. Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med. (2000)
  59. Sarris J, Byrne GJ. A systematic review of insomnia and complementary medicine. Clin Rev. (2011)
  60. Roth T, Roehrs T. Efficacy and Safety of Sleep-Promoting Agents. Sleep Med Clin. (2008)
  61. Pakseresht S, Boostani H, Sayyah M. Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study. J Complement Integr Med. (2011)
  62. Nam SM, et al. Valeriana officinalis extract and its main component, valerenic acid, ameliorate d-galactose-induced reductions in memory, cell proliferation, and neuroblast differentiation by reducing corticosterone levels and lipid peroxidation. Exp Gerontol. (2013)
  63. Wheatley D. Kava and valerian in the treatment of stress-induced insomnia. Phytother Res. (2001)
  64. Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol. (2001)
  65. Palesh OG, et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol. (2010)
  66. Davidson JR, et al. Sleep disturbance in cancer patients. Soc Sci Med. (2002)
  67. Miller AH, et al. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. (2008)
  68. Singh A, et al. Prevalence and severity of dysmenorrhea: a problem related to menstruation, among first and second year female medical students. Indian J Physiol Pharmacol. (2008)
  69. Unsal A1, et al. Prevalence of dysmenorrhea and its effect on quality of life among a group of female university students. Ups J Med Sci. (2010)
  70. Tavallaee M, et al. The prevalence of menstrual pain and associated risk factors among Iranian women. J Obstet Gynaecol Res. (2011)
  71. Gilani AH, et al. Antispasmodic and blood pressure lowering effects of Valeriana wallichii are mediated through K+ channel activation. J Ethnopharmacol. (2005)
  72. Mirabi P, et al. Effects of valerian on the severity and systemic manifestations of dysmenorrhea. Int J Gynaecol Obstet. (2011)
  73. Mirabi P, Mojab F. The effects of valerian root on hot flashes in menopausal women. Iran J Pharm Res. (2013)
  74. Taavoni S, et al. Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial. Menopause. (2011)
  75. Bhatt C, et al. Synergistic potentiation of anti-anxiety activity of valerian and alprazolam by liquorice. Indian J Pharmacol. (2013)
  76. Cuellar NG, Ratcliffe SJ. Does valerian improve sleepiness and symptom severity in people with restless legs syndrome. Altern Ther Health Med. (2009)
  77. Takeshita S, Takeshita J. A case of hyponatremia due to self-treatment of anxiety with a beverage containing valerian root. Prim Care Companion CNS Disord. (2013)
  78. Behboodi Moghadam Z, et al. The effect of Valerian root extract on the severity of pre menstrual syndrome symptoms. J Tradit Complement Med. (2016)